glp-1 therapy weight loss milestones timeline Upgrading from Overweight: The Effects of Drugs on the Investment Landscape Long-Term Weight Loss with GLP-1

DPP-4 inhibitors repress NLRP3 inflammasome and interleukin-1beta via GLP-1 receptor in macrophages through protein kinase C pathway

They also carry more side effects, higher costs, and require ongoing medical supervision

WHERE TO PLAY NEXT: MOST ATTRACTIVE GROWTH OPPORTUNITIES Where the Best Expansion Logic Sits Most Attractive Product Niches Most Attractive Customer Segments White Spaces and Unsaturated Opportunities High-Margin and Underpenetrated Pockets Most Promising Product Adjacencies 14

in such cases, a DPP-4 inhibitor is often the next choice

But now new evidence is pouring in for potential benefits that extend far beyond weight loss